Technical Analysis for AEZS - Aeterna Zentaris Inc
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 2.670 | 0.00% | 0.000 |
Earnings due: May 7
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | -3.26% | |
| Narrow Range Bar | Range Contraction | -3.26% | |
| Gapped Up | Strength | -3.26% | |
| Oversold Stochastic | Weakness | -3.26% | |
| Bollinger Band Squeeze | Range Contraction | -1.11% | |
| Narrow Range Bar | Range Contraction | -1.11% |
| Alert | Time |
|---|---|
| Fell Below Previous Day's Low | 1 day ago |
| Down 3% | 1 day ago |
| Down 2% | 1 day ago |
| Down 1% | 1 day ago |
| Rose Above Previous Day's High | 4 days ago |
Get this analysis on your stocks daily!
- Earnings date: 2024-05-07
Aeterna Zentaris Inc Description
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company's principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company's direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Pharma Pharmaceutical Clinic Drug Biotechnology Leasing Life Sciences Oncology Biopharmaceutical Drug Development Peptides Hormone
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.88 |
| 52 Week Low | 1.91 |
| Average Volume | 2,251 |
| 200-Day Moving Average | 3.019 |
| 50-Day Moving Average | 2.642 |
| 20-Day Moving Average | 2.786 |
| 10-Day Moving Average | 2.751 |
| Average True Range | 0.095 |
| RSI (14) | 45.36 |
| ADX | 33.26 |
| +DI | 36.207 |
| -DI | 31.750 |
| Chandelier Exit (Long, 3 ATRs) | 2.776 |
| Chandelier Exit (Short, 3 ATRs) | 2.954 |
| Upper Bollinger Bands | 2.922 |
| Lower Bollinger Band | 2.649 |
| Percent B (%b) | 0.08 |
| BandWidth | 9.808 |
| MACD Line | 0.011 |
| MACD Signal Line | 0.034 |
| MACD Histogram | -0.0231 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.670 | ||||
| Resistance 3 (R3) | 2.670 | 2.670 | 2.670 | ||
| Resistance 2 (R2) | 2.670 | 2.670 | 2.670 | 2.670 | |
| Resistance 1 (R1) | 2.670 | 2.670 | 2.670 | 2.670 | 2.670 |
| Pivot Point | 2.670 | 2.670 | 2.670 | 2.670 | 2.670 |
| Support 1 (S1) | 2.670 | 2.670 | 2.670 | 2.670 | 2.670 |
| Support 2 (S2) | 2.670 | 2.670 | 2.670 | 2.670 | |
| Support 3 (S3) | 2.670 | 2.670 | 2.670 | ||
| Support 4 (S4) | 2.670 |
